INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE EVIDENCE INDEX

The Study Library.

8,456 peer-reviewed studies, each with a short note written from its published abstract: what kind of study it was, who took part, what was measured and what the authors reported. Observational studies show associations, not proof.

Showing studies that examined mushrooms. Clear

People assigned to a diet, food or program and measured.

3 studies

2015 / Phase I trial

White button mushroom powder showed biological activity in biochemically recurrent prostate cancer.

Thirty-six patients with rising prostate-specific antigen levels received escalating doses of white button mushroom powder in a phase I trial. No dose-limiting toxicities occurred, and the overall prostate-specific antigen response rate was 11%. Complete responses occurred in two patients receiving 8 and 14 g/d, with reductions to undetectable levels lasting 49 and 30 months.

Twardowski P, Kanaya N, Frankel P, et al. Cancer, 2015. PMID 25989179

2010 / Open-label study

Neither Agaricus blazei nor Ganoderma lucidum mushroom supplements showed significant anticancer effects in prostate cancer patients with biochemical failure.

In an open-label study, 51 patients with biochemical failure following radical prostatectomy for non-metastasized prostate cancer took either Senseiro (Agaricus blazei Murill extract, n=32) or Rokkaku Reishi (Ganoderma lucidum, n=15) for 6 months. Forty-seven patients completed the protocol and were assessed. No partial response (a 50% or greater decrease in serum PSA) was observed in any patient. Alteration of PSA doubling time did not correlate with serum testosterone levels, and no serious adverse effects were observed.

Yoshimura K, Kamoto T, Ogawa O, et al. Int J Urol, 2010. PMID 20412340

2002 / Open-label clinical trial

Shiitake mushroom mycelium extract did not lower PSA levels in prostate cancer.

Sixty-two men with histologically proven prostate cancer and elevated PSA received shiitake mushroom mycelium extract capsules three times daily for 6 months. Among 61 assessable patients, zero achieved a complete or partial PSA response, 23 developed disease progression, and 38 maintained stable PSA levels. When pre-study PSA trajectories were examined, only 4 of 61 patients (7%) demonstrated stabilized disease while taking the supplement.

deVere White RW, Hackman RM, Soares SE, et al. Urology, 2002. PMID 12385925